News

Results showed a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint for Tagrisso versus gefitinib or erlotinib, both of which were previous standard-of-care (SoC)

GPA and MPA are rare and potentially life-threatening diseases, which affect small and medium-sized blood vessels. The FDA approval was based on data from the PePRS phase IIa,

Niraparib delivered the desired result when given as monotherapy in the patient population, irrespective of biomarker status. The results of the PRIMA trial were presented at the 2019

The study results will be presented for the first time today at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. “Data from this study

ST266 is a novel “secretome,” cell-free platform biologic, containing hundreds of proteins and other biological factors involved in cellular healing. For delivery to the optic nerve and brain,

The regulator has expanded the use of Dysport for injection to treat upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral

“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and their patients,” said Jim Lee, M.D., Ph.D., Group

“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D.,

The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the treatment of cataplexy and excessive daytime sleepiness (EDS) in